Get the Stockscreener App
1.31
4.38%
-0.06
After Hours:
1.31
Lexicon Pharmaceuticals Inc stock is traded at $1.31, with a volume of 1.66M.
It is down -4.38% in the last 24 hours and up +11.02% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$1.37
Open:
$1.36
24h Volume:
1.66M
Relative Volume:
0.67
Market Cap:
$547.40M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-1.6375
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
+11.02%
1M Performance:
+11.02%
6M Performance:
+23.58%
1Y Performance:
+88.49%
1-Day Range:
$1.29
$1.37
1-Week Range:
$1.17
$1.385
52-Week Range:
$0.2836
$1.83
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.31 | 572.48M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Sentiment Recap: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteriaTrade Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Lexicon Pharmaceuticals completes $100 million stock offering By Investing.com - Investing.com Nigeria
Lexicon Pharmaceuticals completes $100 million stock offering - Investing.com
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - The Manila Times
Lexicon Pharmaceuticals Completes Public Offering of Common Stock and Concurrent Private Placement - Quiver Quantitative
Lexicon raises about $94.6M to fund drug work and operations - Stock Titan
Lexicon Pharmaceuticals prices $94.6M share offering - MSN
Insider Buying: Lexicon Pharmaceuticals (NASDAQ:LXRX) Director Acquires 1,538,462 Shares of Stock - MarketBeat
Market Review: How does Lexicon Pharmaceuticals Inc compare to its peersWeekly Market Outlook & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Lexicon Pharmaceuticals Bolsters Capital Through Equity Financing - The Globe and Mail
Lexicon Pharmaceuticals Signs Multiple Material Agreements - TradingView
FOMO Trade: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteria2025 Momentum Check & Capital Protection Trade Alerts - baoquankhu1.vn
Lexicon Pharmaceuticals Initiates Stock Offering to Drive R&D Growth - StocksToTrade
Lexicon Pharmaceuticals Stock Offering: Strategic Move to Boost R&D - timothysykes.com
Pullback Watch: Can Lexicon Pharmaceuticals Inc reach all time highs this yearWeekly Trading Summary & Technical Pattern Alert System - baoquankhu1.vn
Lexicon Pharmaceuticals Announces Key Stock Offering amid Strategic Funding Efforts - StocksToTrade
Lexicon Pharmaceuticals prices public offering at $1.30 per share By Investing.com - Investing.com Nigeria
Lexicon Pharmaceuticals launches public offering of common stock By Investing.com - Investing.com Australia
Citi Raises Lexicon Pharmaceuticals (LXRX) Outlook on Strength of Novo Nordisk Partnership Milestones - Finviz
Lexicon Pharmaceuticals stock tumbles on public offering pricing By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals (LXRX) Engages Jefferies and Piper Sandl - GuruFocus
Lexicon Pharmaceuticals stock tumbles on public offering pricing - Investing.com India
Lexicon Pharmaceuticals (LXRX) Raises $41.6M Through Public Offe - GuruFocus
Lexicon Pharmaceuticals prices public offering at $1.30 per share - Investing.com
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - The Manila Times
Lexicon announces pricing of approximately $94.6 million public offering at $1.30 per share - marketscreener.com
Drug developer Lexicon raises $94.6M to fund pipeline and operations - stocktitan.net
Lexicon Pharmaceuticals (LXRX) Initiates Public Stock Offering - GuruFocus
Lexicon Pharmaceuticals (LXRX) Launches Public Offering, Shares Dip - GuruFocus
Lexicon Pharmaceuticals launches public offering of common stock - Investing.com
Lexicon Announces Proposed Public Offering of Common Stock - The Manila Times
Lexicon (NASDAQ: LXRX) plans stock sale, highlights late-stage pipeline - stocktitan.net
Lexicon plans stock sale to fund drug candidate research, operations - Stock Titan
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Down 8.5%Should You Sell? - MarketBeat
Lexicon Pharmaceuticals Rings the Closing Bell - Nasdaq
How A Reset Price Target Is Reframing The Story For Lexicon Pharmaceuticals (LXRX) - Yahoo Finance
Risk Report: Can Lexicon Pharmaceuticals Inc reach all time highs this year - baoquankhu1.vn
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Lexicon Pharma spikes after FDA feedback on pain drug - MSN
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shows High-Growth Momentum with Strong Technical and Fundamental Trends - ChartMill
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary - Yahoo Finance
Downgrade Watch: How does Lexicon Pharmaceuticals Inc compare to its peersJuly 2025 Pullbacks & Safe Entry Trade Reports - baoquankhu1.vn
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):